← Back to patent-cliff list
Vortosiran
Tier C — Watch / tradeVortosiran
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：F11, ASGPR
Indications (approved)：Coronary artery lesion, Coronary artery disease, Venous thrombosis, End-stage renal disease
Regional status
US
-
EU
Phase II
2024-05-29
China
IND filed
2026-09-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vortosiran?
Approved indications include: Coronary artery lesion, Coronary artery disease, Venous thrombosis, End-stage renal disease.
When does the Vortosiran patent expire?
No public expiry year is available for Vortosiran yet; this page updates once verified.
How do I get a quote for Vortosiran intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01